Skip to main content
. Author manuscript; available in PMC: 2009 Jul 1.
Published in final edited form as: Cancer Res. 2008 Jul 1;68(13):5023–5030. doi: 10.1158/0008-5472.CAN-07-6189

Figure 2.

Figure 2

Characterization of BRCA2-null cells. A, immunofluorescence of RAD51 nuclear foci in untreated and treated cells (2.4 μg/mL MMC). BRCA2 +/−, BRCA2wt/Δex11; BRCA2−/−, BRCA2Δex11/Δex11. B, analysis of 50 metaphases for chromosomal aberrations in untreated and treated (equitoxic doses of MMC) heterozygous and knockout clones. C.1, colony formation assays on irradiation. BRCA2 par, parental BRCA2wt/mut × 2. Points, mean of three independent experiments; bars, SE. C.2, cell cycle analysis 48 h after MMC treatment. Representative cell cycle profiles obtained after treatment with indicated concentrations of MMC. D, cell proliferation following treatment with selected drugs. Two BRCA2 −/− (BRCA2Δex11/Δex11) subclones were analyzed. Points, mean of three independent experiments; bars, SE.